You are not connected. The newsletter may include some user information, so they may not be displayed correctly.

ASCIA Update 15 January 2024

ASCIA Update 15 January 2024

‍‍ ‍ ‍ ‍Click here to view it online

15 January 2024

--

New ASCIA Strategic Plan 2024-2028

To coincide with the start of 2024, a new ASCIA Strategic Plan 2024-2028 is now available open access on the ASCIA website, which is based on:

  • ASCIA’s Purpose, Strategic Areas of Focus and Priorities
  • Findings from the ASCIA Priorities Report 2022-2023
  • National Allergy Council projects assigned to ASCIA
  • ASCIA Immunodeficiency Strategy priorities

Read more here

--

ASCIA Website Resources

The ASCIA website is continuously reviewed and updated to improve the user experience and make it easier to find ASCIA resources, which include:

Read more here

--

ASCIA Highlights 2022-2023 

A major highlight of 2023 was the ASCIA Conference, which was a highly successful hybrid event with over 700 delegates (72% in-person) in Sydney, 5-8 September.

Other highlights include hosting an implementation meeting for the ASCIA Immunodeficiency Strategy and progress on the National Allergy Council Shared Care and Schools/Childcare projects.

Read more here

--

ASCIA Course for Dietitians Save the Date – 9th to 10th May 2024

The next ASCIA Food Allergy and Adverse Food Reactions Course for Dietitians will be held in Adelaide on Thursday 9th to Friday 10th May 2024.

This course has an interactive in-person program that is focused on medical nutrition therapy in food allergy and intolerance.

Registration will open in February 2024.

Further information is available here

--

New and Updated Immunodeficiency Information

New Newborn Screening for Severe Combined Immune Deficiency (SCID) and BCG Vaccination - Position Statement for health professionals

New Newborn Screening for Severe Combined Immune Deficiency (SCID) - FAQ for patients and carers

New National Blood Authority Subcutaneous Immunoglobulin Report

New Subcutaneous Immunoglobulin (SCIg) products

New Transition from Evogam to Hizentra AU SCIg products

New ASCIA Laboratory Tests for Autoimmune Diseases Position Paper

Updated ASCIA IVIg Infusion Guidelines

--

New and Updated Allergy Information

New Edible Insect Food Allergy Survey - open until 9 February 2024

Updated ASCIA Dietary Avoidance for Food Allergy FAQ

New ASCIA Management Plan for Delayed Allergic Reactions to Foods

Updated ASCIA Guide for Milk Substitutes in Cow’s Milk Allergy

Updated ASCIA Treatment Plan for Allergic Rhinitis

New and updated ASCIA VIT and AIT FAQ and consent forms  

--

Recent National Allergy Council Updates

A Survey to Improve Allergy Training in Tertiary Healthcare Degrees is open until 17 February 2024, as part of the Shared Care project.

Updated Best Practice Guidelines for anaphylaxis prevention and management in schools and children’s education/care services are available on the re-designed Allergy Aware website.

Nip allergies in the Bub website has been re-designed, to make it easier for parents to find information about food allergy prevention and eczema.

--

Product Availability – Recent Updates

Monovalent COVID-19 Omicron XBB.1.5 vaccines

Shingrix® varicella zoster virus recombinant vaccine

Jorveza® for the treatment of eosinophilic oesophagitis (EoE)

Dymista® Allergy nasal spray for treatment of allergic rhinitis – now OTC

--

Reminder - PBAC Meeting March 2024 – feedback due 31 Jan 2024

Consultation has opened for the March 2024 Pharmaceutical Benefits Advisory Committee (PBAC) agenda and feedback is due by 31 January 2024. This includes submissions for new or updated Pharmaceutical Benefits Scheme (PBS) listings of products that are relevant to allergy and immunology.

Read more here

--

Reminder - Allergy and Immunology Research

Donate here to support AIFA allergy and immunology research grants in 2024. All donations go directly to fund AIFA research grants. 

Apply here for the Grifols ASPIRE Award (by 31 March 2024) for research projects that improve immunodeficiency awareness, diagnosis and therapy.

The ASCIA website includes information about current allergy and immunology research in Australia and New Zealand.

--

Reminder - Red Imported Fire Ants in Australia - Senate Inquiry

There is currently a call for submissions to a Senate Inquiry for the potential impacts of Red Imported Fire Ants (RIFA) on the health of Australians, as well as costs. RIFA stings can cause large local allergic reactions and anaphylaxis. The closing date for submissions has been extended to 29 January 2024.

Read more here

--

Regularly Updated ASCIA Webpages

The following ASCIA webpages are regularly updated:

ASCIA Reports

Locate a Specialist

ASCIA Submissions

Allergy/Immunology Positions

Conference, Meetings and Events Calendar

 

ASCIA gratefully acknowledges the generous support of all sponsors listed on the ASCIA website www.allergy.org.au/about-ascia/sponsors



ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand.  

ASCIA Updates provide current information to the community about allergy and other immune system disorders.

AIFA

AIFA is dedicated to improving the health of people with allergy and other immune system disorders by providing AIFA allergy and immunology research grants. 


‍‍ ‍ ‍ ‍ ‍ ‍Unsubscribe to ASCIA Update